Open Access

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

  • Authors:
    • Matthias Villalobos
    • Piotr Czapiewski
    • Niels Reinmuth
    • Jürgen R. Fischer
    • Stefan Andreas
    • Cornelius Kortsik
    • Monika Serke
    • Martin Wolf
    • Petra Neuser
    • Alexander Reuss
    • Philipp A. Schnabel
    • Michael Thomas
  • View Affiliations

  • Published online on: March 15, 2019     https://doi.org/10.3892/ol.2019.10153
  • Pages: 4891-4900
  • Copyright: © Villalobos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to assess the expression of epithelial‑mesenchymal transition biomarkers (E‑cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non‑squamous non‑small cell lung cancer (NSCLC) enrolled in the INNOVATIONS trial, receiving treatment with either erlotinib/bevacizumab (EB) or cisplatin/gemcitabine/bevacizumab (PGB). The tumor tissues of 104 patients were retrospectively analyzed using immunohistochemistry to assess the expression of E‑cadherin and vimentin. The distribution between the treatment arms was 46 patients in the EB‑arm and 58 in the PGB‑arm. Comparing the treatment arms according to E‑cadherin and vimentin expression, the analysis revealed that progression‑free survival (PFS) was increased in the PGB treatment group when compared with EB treatment in patients with low expression of E‑cadherin [hazard ratio (HR)=0.353; 95% confidence interval (CI) 0.189‑ 0.658; log‑rank P=0.0007] and in those with high expression of vimentin [HR=0.276 (95% CI, 0.115‑ 0.659), log‑rank P=0.0021]. In patients that exhibited high E‑cadherin and were negative for vimentin, there was no difference in the PFS between the PGB and EB treatment groups. In conclusion, in non‑squamous NSCLC with downregulated E‑cadherin and upregulated vimentin, the efficacy of chemotherapy with PGB was superior compared with EB; but the same effect was not observed in patients with high E‑cadherin and low vimentin. Although increased PFS was observed in patients with PGB treatment compared with EB treatment in the whole analysis populations, in the subgroup of patients with the mesenchymal phenotype, no prognostic or predictive value of either biomarker could be identified. The potential role of bevacizumab in overcoming chemotherapy resistance in the population with the mesenchymal phenotype has to be further explored.

References

1 

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, et al: Overall survival with crizotinib and next generation ALK-inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINAKL): A French nationwide cohort retrospective study. Oncotarget. 8:21903–21917. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 18:1307–1316. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Shea M, Costa DB and Rangachari D: Management of advanced non-small cell lung cancers with known mutations or rearrangements: Latest evidence and treatment approaches. Ther Adv Respir Dis. 10:113–129. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D and Myers JN: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 29:2047–2059. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Burdsal CA, Damsky CH and Pedersen RA: The role of E-cadherin and integrins in mesoderm differentiation and migration at the mammalian primitive streak. Development. 118:829–844. 1993.PubMed/NCBI

9 

Lee YC, Wu CT, Chen CS and Chang YL: E-cadherin expression in surgically-resected non-small cell lung cancers-a clinicopathological study. Thorac Cardiovasc Surg. 48:294–299. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T and Sugimachi K: Expression of E-cadherin and ß-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 6:4789–4796. 2000.PubMed/NCBI

11 

Choi YS, Shim YM, Kim SH, Son DS, Lee HS, Kim GY, Han J and Kim J: Prognostic significance of E-cadherin and ß-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 24:441–449. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Richardon F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, Davies A, Epstein PM and Wacker B: The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- and third-line therapy. Anticancer Res. 32:537–552. 2012.PubMed/NCBI

13 

Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H and Wang C: Clinical significance or E-cadherin, ß-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 66:937–945. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Voon DC, Huang RY, Jackson RA and Thiery JP: The EMT spectrum and therapeutic opportunities. Mol Oncol. 11:878–891. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thierry JP and Chouaib S: New insights into the role of EMT in tumor immune escape. Mol Oncol. 11:824–846. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Gark AD, Dudek-Peric A, Romanio E and Agostinis P: Immunogenic cell death. Int J Dev Biol. 59:131–140. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Sato M, Shames DS and Hasegawa Y: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Zhihua Y, Zhang X, Luo Y, Li S, Huang L, Li Z, Li P and Chen G: Prognostic values of vimentin expression and its clinicopathological significance in non-small cell lung cancer: A meta-analysis of observational studies with 4118 cases. PLoS One. 11:e01631622016. View Article : Google Scholar : PubMed/NCBI

20 

Dauphin M, Barbe C, Lemaire S, Nawrocki-Raby B, Lagonotte E, Delepine G, Birembaut P, Gilles C and Polette M: Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer. 81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Sui H, Zhu L, Deng W and Li Q: Epithelial-mesenchymal transition and drug resistance: Role, molecular mechanisms and therapeutic strategies. Oncol Res Treat. 37:584–589. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 11:8686–8698. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, et al: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI

24 

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI

25 

Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, et al: Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. Eur Respir J. 46:219–229. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Wu Y, Liu H, Ding M, Liu J, Zhan P, Fu X and Gan L: The impact of E-cadherin expression on non-small cell lung cancer survival: A meta-analysis. Mol Biol Rep. 39:9621–9628. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Ren S, Su C, Wang Z, Li J, Fan L, Li B, Li X, Zhao C, Wu C, Hou L, et al: Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. Int J Cancer. 135:2962–2971. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C and Allgayer H: Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res. 69:2461–2470. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P and Hainsworth J: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet. 377:1846–1854. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosorni Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomized, mutlicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massuti B, Palmero R, Aix SP, Carcereny E, et al: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 5:435–444. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C and Wistuba II: Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 22:668–678. 2009. View Article : Google Scholar : PubMed/NCBI

34 

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, et al: Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomized controlled trial. Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomized phase 3 trial. Lancet. 384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI

36 

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomized controlled trial. Lancet Oncol. 15:143–155. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U, Bentires-Alj M and Christofori G: VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res. 74:1566–1575. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Yi ZY, Feng LJ, Xiang Z and Yao H: Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J Invest Surg. 24:67–76. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Li Y, Yang X, Su LJ and Flaig TW: VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cell. Oncol Rep. 24:1019–1028. 2010.PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J.R., Andreas, S., Kortsik, C. ... Thomas, M. (2019). Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncology Letters, 17, 4891-4900. https://doi.org/10.3892/ol.2019.10153
MLA
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. R., Andreas, S., Kortsik, C., Serke, M., Wolf, M., Neuser, P., Reuss, A., Schnabel, P. A., Thomas, M."Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab". Oncology Letters 17.6 (2019): 4891-4900.
Chicago
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. R., Andreas, S., Kortsik, C., Serke, M., Wolf, M., Neuser, P., Reuss, A., Schnabel, P. A., Thomas, M."Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab". Oncology Letters 17, no. 6 (2019): 4891-4900. https://doi.org/10.3892/ol.2019.10153